-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Edoxaban is an oral direct factor Xa inhibitor used for the prevention and treatment of deep vein thrombosis and pulmonary embolism.
The synthetic routes of Edoxaban tosylate have been extensively studied and developed due to its important role in the pharmaceutical industry.
The synthesis of Edoxaban tosylate involves several stages, including the synthesis of the basic structure of the compound, the introduction of the tosylate group, and the final step of converting the intermediate to the final product.
The synthesis of the basic structure of Edoxaban tosylate can be accomplished through several different methods.
One common method involves the reaction of 3-nitro-4-[2,3-dihydro-1H-indol-1-yl]benzaldehyde with 2,2'-diamino-5,6-dihydroimidazo[1,2-d][1,4]benzoxepin-3-one in the presence of a solvent such as acetonitrile.
This reaction results in the formation of the corresponding imine, which can then be reduced using a reducing agent such as sodium borohydride to form the final amine.
Once the basic structure of Edoxaban tosylate has been synthesized, the tosylate group can be introduced through a variety of methods.
One common method involves the reaction of the amine with tosyl chloride in the presence of a solvent such as DMF.
This reaction results in the formation of the corresponding tosylate, which can then be further converted to the final product.
The final step in the synthesis of Edoxaban tosylate involves the conversion of the tosylate intermediate to the final product.
This can be accomplished using several different methods, such as hydrogenation or silylation.
The final product is then purified and characterized to ensure its purity and identity.
The synthetic routes of Edoxaban tosylate have been extensively studied and developed due to its important role in the pharmaceutical industry.
Edoxaban is an oral direct factor Xa inhibitor used for the prevention and treatment of deep vein thrombosis and pulmonary embolism, and its synthesis has been developed through several stages, including the synthesis of the basic structure, the introduction of the tosylate group, and the final step of converting the intermediate to the final product.
The synthetic routes of Edoxaban tosylate have been demonstrated to be reliable and efficient, and have enabled the production of large quantities of this important compound for use in the pharmaceutical industry.